11th Annual Retrovirus Conference

Conference Reports for NATAP


11th Annual Retrovirus Conference (CROI-Conference on Retroviruses and Opportunistic Infections) San Francisco Feb 8-11, 2004

	5-Year Results of Lopinavir/ritonavir (LPV/r)-Based Therapy in Antiretroviral-Naïve HIV-Infected Patients - (04/12/04) Body Changes, Toxicity, Efficacy: d4T vs Abacavir, plus 3TC/EFV - (04/12/04) EPO Once Weekly Improves Anemia & Quality of Life in Coinfected Patients Treated with Interferon/Ribavirin - (03/29/04) Re-Examining Rosiglitazone for Lipoatrophy - (03/24/04) Treating Acute HIV Infection and Treatment Interruptions to Boost Immune Control: an experiment comes to an end - Written by David Margolis, MD (03/24/04) CROI Report: Pharmacology of HIV Drugs - Written for NATAP by Peter Anderson, PhD (03/18/04) Hypertension and HIV & ART - Written for NATAP by Judith A. Aberg, M.D. (03/17/04) Alendronate And Osteopenia and Osteoporosis - (03/17/04) Quantification of Hepatitis B Virus-specific T-cell Responses in HIV/HBV Co-infected Individuals - (03/15/04) Insulin Resistance/Diabetes and HIV and Hepatitis C; Aging/HIV & diabetes - written by Judith A. Aberg, M.D. (03/08/04) Evaluation of HCV RNA and Liver Injury in HCV/HIV Coinfected Patients Initiating Lopinavir/r or Nelfinavir-based Therapy - (03/08/04) CROI Report- HIV/HCV Co-Infection: Organ Transplantation and Liver Cancer - (03/08/04) CROI Resistance Report 7: New Drugs—Reyataz; TMC-114; Reverset - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/05/04) CROI Resistance Report 6: Single Drug Interruption Strategy--nrti, nnrti, pi - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/05/04) CROI Resistance Report 5: the K65R Mutation, its relevance, prevalence, & mechanism of action - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/05/04) CROI Resistance Report 4: Certain, But Not All, Triple Nuke Regimens Have High Viral Failure Rate - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/03/04) CROI Resistance Report 3: Nevirapine Effect & The Development of Drug Resistance in Preventing Mother to Child HIV Transmission - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/03/04) CROI Resistance Report, Part 2; Transmission of Drug Resistance, it Persists; Global Trends; Impact of Transmitted Resistance on Initial Response to HAART - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/03/04) CROI: HIV-1 Drug Resistance Review Report 1: Low Level NNRTI Resistance May Not Be Detected by Standard Genotype Tests; Sensitive Genotype Tests - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/03/04) Hepatitis A Vaccine in HIV+: Low Response Rates Seen in Study - (03/03/04) Hepatitis B Treatment Update - Nancy Shulman, MD, Stanford University (03/02/04) Tenofovir is Effective Against HBV in HBV/HIV Coinfection - (03/03/04) CROI Report: HIV-1 Drug Resistance Review - Written for NATAP by Andrew Zolopa, MD, Stanford University (03/03/04) Three Year Treatment with Adefovir in Chronic Hepatitis B Patients with Lamivudine (3TC) Resistant HBV and HIV Coinfection Results in Significant and Sustained Clinical Improvement - (03/02/04) Changes in Renal Function in Patients Treated with Tenofovir DF vs Nucleoside Reverse Transcriptase Inhibitors - (03/02/04) Effects of Fuzeon on Body Composition and Lipids Through 48 weeks in the TORO Trials - (03/02/04) PK Report-Double Boosted Protease Inhibitor Regimens: Reyataz/SQV/r; SQV/Fosamprenavir/r; PK highlights - Written for NATAP By Ronald Reisler MD MPH, Institutes of Human Virology University of Maryland Medical School (03/02/04) Protease Inhibitors and Utility Of Inhibitory Quotients: high dose Kaletra may overcome PI resistance; Reyataz Expanded Access; Lipids & Kaletra Drug levels - Written for NATAP By Ronald Reisler MD MPH, Institutes of Human Virology University of Maryland Medical School (03/01/04) NNRTI's -- New Insights- "THE NNRTI TAIL": drug resistance; prevention of mother-to-child HIV transmission; HAART interruption - Written for NATAP By Ronald Reisler MD MPH, Institutes of Human Virology University of Maryland Medical School (03/01/04) The Effect of Smoked Marijuana on Chronic Neuropathic and Experimentally Induced Pain in HIV Neuropathy: Results of an Open-label Pilot Study - (03/01/04) Marijuana Relieves HIV Neuropathy in Preliminary Trial - (03/01/04) Reyataz Expanded Access: lipids, viral response, safety - (02/26/04) Interesting CROI Poster Highlights: nukes/RBV, CSF/HAART, 3-PI regimens, APV/Kaletra, single drug interruption, fitness - Reported by David Margolis, MD, University of Texas, Southwestern Medical Center (02/26/04) HIV Latency: still trying to figure it out; is HIV curable? - Report by David Margolis, MD, University of Texas, Southwestern Medical Center (02/26/04) Hepatitis C and HIV: incremental advances; plenary talk on HCV protease, new drug research & basic science; final results of 3 important co-infection studies - Reported for NATAP by David Margolis, MD, University of Texas, Southwestern Medical Center (02/26/04) Peg/RBV treatment, liver transplants, RBV/nuke interaction study, HCV & HAART response - Reported by Nancy Shulman, MD, Stanford University (02/26/04) Neuropathogenic Manifestations of HIV Infection and Its Therapy: report from CROI - Written by Justin C. McArthur, MBBS, MPH, Johns Hopkins University Medical School (02/26/04) HCV/HIV Coinfection May Cause Depression & Cognitive Dysfunction Compared to HIV Monoinfection - (02/26/04) Nevirapine Resistance Develops in Therapy to Prevent Mother-To-Child Transmission - Written by David Margolis, MD, University of Texas Southwestern Medical Center (02/26/04) Once-Daily vs.Twice-Daily Lopinavir/ritonavir in Antiretroviral-NaÔve Patients: 48-Week Results - (02/26/04) High Dose Kaletra in Highly Experienced Patients - (02/23/04) HIV Microbocides at the 11th Retrovirus Conference - (02/23/04) Incidence of Non-AIDS defining Malignancies in the HIV Outpatient Study (HOPS) Higher Than General Population - (02/23/04) Troubling Persistence of Transmitted HIV Drug Resistance - Reported for NATAP by David Margolis, MD(02/20/04) Standard Genotype Tests May Not Detect Low Level Resistance; new Super-Sensitive Resistance Tests - Reported for NATAP by David Margolis, MD(02/20/04) Kaletra Once Daily (48 Week results) - Reported for NATAP by Dr Graeme Moyle (02/20/04) GW873140, New HIV Drug, Novel CCR5 Inhibitor - (02/20/04) Tolerance and Potent AntiHIV Activity of Reverset Following 10 Days of Monotherapy in Treatment Naïve Individuals - (02/20/04) 1 vs 2 Protease Inhibitors in Patients With Viral Failure on Initial PI Regimen: CPCRA 057 - Written by Grame Moyle, MD (02/20/04) Protease Inhibitor (PI) Experienced patients: therapeutic approaches, ritonavir-boosted regimens - Written by Grame Moyle, MD (02/20/04) New antiretroviral agents at 2004 Retrovirus Conference - Reported for NATAP by Mike Youle, MD (02/20/04) TNX-355, new HIV Drug, is Safe & Effective in Multiple Dose Phase 1 Study: - (02/20/04) PegIntron Plus Ribaivin in HCV/HIV Coinfection: French RIBAVIC Study - (02/19/04) ACTG 5071: Pegasys plus Ribavirin vs IFN/RBV in HCV/HIV Coinfection - (02/19/04) Body Shape at CROI: rosiglitazone, Newfill, Fuzeon, PI-switch study, d4T-XR, FTC, face ultrasound, Atlantic & NEFA studies - Written by David Alain Wohl, MD (02/19/04) The Effect of Atazanavir vs Lopinavir/ritonavir on Insulin-Stimulated Glucose Disposal Rate in Healthy Subjects - (02/17/04) No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial - (02/17/04) SCH-D, CCR5 Receptor Inhibitor, new HIV Drug in New Class of Drugs: - (02/13/04) HIV Vaccine $$, ADAP & Hepatitis - (02/13/04) New HIV Drug & New Class of HIV Drugs: BMS-488043, an attachment Inhibitor - (02/12/04) Ribavirin-NRTIs Interaction Study - (02/12/04) High HIV Rates in NYC & Among Black & MSM/W College Students; Men On The 'Down Low' - (02/12/04) Pegylated Interferon plus Ribavirin: Pegasys/RBV in Co-infection (APRICOT Study, 72-week results) - (02/11/04) Reyataz/r Compared to Kaletra (study 045): 48 week data - (02/11/04) Hepatitis C and Neuropsychological Function In Treatment Naive HIV-1-infected Subjects - A5097s Baseline Analysis - (02/09/04) Incidence of HIV Superinfection Following Primary Infection - (02/09/04) Tenofovir Tested for HIV Prevention & Microbicide - (02/09/04)